INFLUENZA PATHOGENESIS AND IMMUNOLOGY RESEARCH CENTER:T CELL RESPONSES

流感发病机制和免疫学研究中心：T 细胞反应

• 批准号: 8357561
• 负责人: John David Altman
• 金额: $ 12.34万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-08-01 至 2012-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8357561
• 关键词: Attenuated; CD4 Positive T Lymphocytes; CD8B1 gene; California; Flushield; Funding; Grant; Human; Immunology; Inactivated Vaccines; Influenza; Life; Measures; National Center for Research Resources; Pathogenesis; Primates; Principal Investigator; Production; Proteins; Recombinants; Research; Research Infrastructure; Resources; Seasons; Source; T cell response; United States National Institutes of Health; Vaccinated; Vaccination; Vaccines; Vesicular stomatitis Indiana virus; Virus; cost; influenza virus vaccine; pandemic disease; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. For assessment of human T cell responses to influenza A and B viruses, we have constructed a large panel of replication-restricted, recombinant vesicular stomatitis viruses, each expressing a single protein from a variety of influenza strains. The complete panel covers the HA and NA proteins from influenza vaccine strains used from 2000-2011, as well as the internal components of the A/California/04/09 strain from the recent pandemic, the PR8 strain that is used for production of the conventional vaccine, and the A/Ann Arbor/06/60 strain that is used for the production of the live-attenuated FluMist vaccine. We are using these to measure T cell responses in 60 donors who were vaccinated during the 2010-2011 season. In general, CD8 T cell responses to vaccination have been low-to-undetectable, a result that was not unexpected, especially for the conventional inactivated vaccine. In contrast, CD4 T cell responses are more frequent, with a response range of 0-631 per million CD4 cells.

该子项目是利用资源的众多研究子项目之一 由 NIH/NCRR 资助的中心拨款提供。子项目的主要支持 并且子项目的主要研究者可能是由其他来源提供的， 包括其他 NIH 来源。 子项目可能列出的总成本 代表子项目使用的中心基础设施的估计数量， NCRR 赠款不直接向子项目或子项目工作人员提供资金。 为了评估人类 T 细胞对甲型和乙型流感病毒的反应，我们构建了一大组复制限制的重组水泡性口炎病毒，每种病毒表达来自多种流感毒株的单一蛋白。完整的面板涵盖了 2000-2011 年使用的流感疫苗株的 HA 和 NA 蛋白，以及最近大流行的 A/California/04/09 株的内部成分，即用于生产流感疫苗的 PR8 株。传统疫苗，以及用于生产减毒活 FluMist 疫苗的 A/Ann Arbor/06/60 菌株。我们正在使用这些来测量 2010-2011 季节期间接种疫苗的 60 名捐赠者的 T 细胞反应。一般来说，CD8 T 细胞对疫苗接种的反应低至无法检测到，这一结果并不出乎意料，特别是对于传统的灭活疫苗。相比之下，CD4 T 细胞反应更为频繁，反应范围为每百万 CD4 细胞 0-631 个。